Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy (IIM)

Next Previous
Search
Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy (IIM)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 1801 (Primary)
  • Indications Dermatomyositis; Myositis; Polymyositis
  • Focus Therapeutic Use
  • Acronyms FROG
  • Sponsors ImmunoForge

Most Recent Events

  • 17 Oct 2023 According to an ImmunoForge media release, the company has dosed the first patient and is currently enrolling patients at 10 university hospitals in South Korea, including Hanyang University Hospital.
  • 17 Oct 2023 According to an ImmunoForge media release, Dr. Dae-Hyun Yoo, is the principal investigator of the Phase 2 study.
  • 11 Sep 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top